Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAsia News India Pharma Roundup: Lupin, Strides Arcolab, GSK India, Nicholas Piramal, Jubilant

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - India's fifth largest generic drug firm Lupin wants to buy other drug formulation companies in the U.S., Latin America, Southeast Asia and the Middle East this year to expand its presence overseas its chairman said after announcing a sharp, but expected, drop in earnings for the fourth quarter ended March 31

You may also be interested in...



Astellas Takes First Steps In India With Prograf

TOKYO - Astellas Pharma said April 12 that its Indian subsidiary has commenced marketing immunosuppressant Prograf (tacrolimus), its flagship product, in India, in the company's first stab at the world's second most populous country

Astellas Takes First Steps In India With Prograf

TOKYO - Astellas Pharma said April 12 that its Indian subsidiary has commenced marketing immunosuppressant Prograf (tacrolimus), its flagship product, in India, in the company's first stab at the world's second most populous country

GSK India Managing Director Hasit Joshipura On What Lies Ahead For India’s Largest Multinational Drug Company: An Interview With PharmAsia News (Part 1 of 2)

GlaxoSmithKline India Managing Director Hasit Joshipura is known as one of the most aggressive multinational pharma directors in India in terms of expansion strategy. Some top GSK officials say he was brought in at the helm with the task of making GSK sharper in its marketing approach. Joshipura presented those capabilities in his earlier stint as the managing director at Johnson & Johnson India. Joshipura sat down with PharmAsia News' India bureau to discuss what lies ahead for India's largest multinational drug company.

Related Content

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel